Prosecution Insights
Last updated: July 17, 2026
Application No. 17/836,053

COMPOSITION AND DEVICE FOR DISINFECTING AIR

Final Rejection §112
Filed
Jun 09, 2022
Priority
Jun 10, 2021 — MO 2711
Examiner
PURDY, KYLE A
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Binova LLC
OA Round
2 (Final)
41%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
78%
With Interview

Examiner Intelligence

Grants 41% of resolved cases
41%
Career Allowance Rate
404 granted / 987 resolved
-19.1% vs TC avg
Strong +37% interview lift
Without
With
+36.7%
Interview Lift
resolved cases with interview
Typical timeline
4y 2m
Avg Prosecution
59 currently pending
Career history
1057
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
75.9%
+35.9% vs TC avg
§102
8.6%
-31.4% vs TC avg
§112
5.8%
-34.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 987 resolved cases

Office Action

§112
DETAILED ACTION Status of Application The Examiner acknowledges receipt of the amendments filed on 4/3/2026 wherein claims 1, 3, 5, 7, 20 have been amended, claims 21 and 22 have been added and claims 2, 4 and 6 have been cancelled Claims 1, 3, 5, 7, 11-15 and 20-22 are presented for examination on the merits. The following rejections are made. Response to Applicants’ Arguments Applicant’s amendments filed 4/3/2026 overcome the rejection of claims 1-4, 6, 7, 11-15 and 20 made by the Examiner under 35 USC 103 over Luthe et al. (US 2021/0341370) in view of Bontchev et al. (US 2017/0210677) and Juodkazis et al. (US 2016/0212989). This rejection has been withdrawn. Applicant’s amendments filed 4/3/2026 overcome the rejection of claim 5 made by the Examiner under 35 USC 103 over Luthe et al. (US 2021/0341370) in view of Bontchev et al. (US 2017/0210677) and Juodkazis et al. (US 2016/0212989) further in view of Xu (US 2018/0213772). This rejection has been withdrawn. Allowable Subject Matter Claims 1, 3, 7, 11-15 and 20-22 are allowed. Withdrawn claims 16-19 appear eligible for rejoinder. Cancellation of withdrawn claims 8-10 is requested. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 3 is rejected under 35 U.S.C. 112(d) as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 3, dependent from claim 1, recites, “wherein the biochar is impregnated, soaked or coated with the biocide.” However, claim 1 limits the structure of the composition such that the biocide “covers at least the apparent surface area and at least part of the inner surface area to form a solid nanometric layer”. As claim 1 requires the biocide to ‘cover’ the surface area of the biochar, this is considered as a coating thereon. Claim 3 appear to expand the scope of claim 1 rather than limit claim 1 via product-by-process limitations as ‘impregnated’ and ‘soaked’ biochar would yield something different than that claimed and as such are not considered further limiting. . Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KYLE A PURDY whose telephone number is (571)270-3504. The examiner can normally be reached from 9AM to 5PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bethany Barham, can be reached on 571-272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /KYLE A PURDY/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Jun 09, 2022
Application Filed
Jun 09, 2022
Response after Non-Final Action
Jan 09, 2026
Non-Final Rejection mailed — §112
Apr 03, 2026
Response Filed
May 28, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12673105
MULTI-FUNCTIONAL CANCER DRUG DELIVERY NANODEVICE FOR PRECISION MEDICINE
5y 9m to grant Granted Jul 07, 2026
Patent 12649000
USE OF ALGINATE OLIGOMERS TO ENHANCE THE TRANSLOCATION OF MICRO/NANOPARTICLES ACROSS MUCUS LAYERS
5y 8m to grant Granted Jun 09, 2026
Patent 12648922
Pet Food Compositions, Method of Treating an Inflammatory Condition and Method of Reducing Ciculatpro-Inflammatory Cytokines
5y 1m to grant Granted Jun 09, 2026
Patent 12648900
Hair restructuring association comprising a quaternary ammonium salt and a sulpho-derivative of vegetable fatty acids
4y 1m to grant Granted Jun 09, 2026
Patent 12636412
COATING COMPOSITION FOR SKIN-CONTACTING SURFACE OF ELASTOMERIC ARTICLES AND ARTICLES CONTAINING THE SAME
6y 4m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
41%
Grant Probability
78%
With Interview (+36.7%)
4y 2m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 987 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month